ArticleTransboundary and emerging diseases2023
A Single Mutation of VP2 is Responsible for the Lethality and Antigenicity Differences between Novel Variant and Very Virulent IBDV Strains.
Article in Transboundary and emerging diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A new recombinant avian metapneumovirus vaccine candidate provides complete protection against the novel variant infectious bursal disease virus in chickens.Veterinary research · 2026Article
- Unraveling VP2 mutations in Infectious Bursal Disease Virus (IBDV) associated with potential vaccine escape in poultry flocks in Shandong, China.Virology journal · 2026Article
- Mapping Molecular Determinants of Antigenicity and Pathogenicity of Infectious Bursal Disease Virus (IBDV): A Scoping Review.Viruses · 2026Article
- Rapid Spread of Novel Infectious Bursal Disease Virus Variant (Genotype A2dB1b) in the Near East and Persian Gulf Regions: Molecular Surveillance and Phylodynamic Reconstruction.Transboundary and emerging diseases · 2026Article
- Pathogenesis and Host Response to A3B4 and A3B2 Infectious Bursal Disease Virus Strains in Chickens.Transboundary and emerging diseases · 2026Article
- Infection Dynamics and Host Responses to Two IPNV Isolates in Liver of Atlantic Salmon (Pathogens (Basel, Switzerland) · 2025Article
- Q221K mutation in VP2 drives antigenic shift of infectious bursal disease virus.Frontiers in immunology · 2025Article
- Molecular characterization of circulating infectious bursal disease viruses in chickens from different Egyptian governorates during 2023.Virology journal · 2024Article
- Immuno-protective effect of commercial IBD vaccines against emerging novel variant infectious bursal disease virus in specific-pathogen-free chickens.Journal of veterinary science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious bursal disease is an acute, immunosuppressive infectious disease in chickens caused by the infectious bursal disease virus (IBDV), which causes huge economic losses to the global poultry industry. Persistently circulating very virulent IBDV (vvIBDV) and newly emerging novel variant IBDV (nVarIBDV) are the two dominant epidemic strains of IBDV in East Asian countries such as China. Compared to lethal vvIBDV, nonlethal nVarIBDV has more insidious pathogenicity and can partially escape the immune protection of the existing vvIBDV vaccine, suggesting its potential adaptive survival strategy. However, the underlying molecular mechanism remains unknown. The viral capsid protein VP2 is closely related to cell tropism, virulence, and antigenic variation of IBDV. In this study, for the first time, we demonstrated that residue 279 of VP2 is responsible for the difference in pathogenicity between nVarIBDV and vvIBDV and that the D279N substitution reduces the lethality of vvIBDV from 70% to 0%. Moreover, a significant reduction in the viral load and inflammatory factor levels in the immune organs and blood of infected chickens may be important mechanisms for reducing the lethality of IBDV. Additionally, residue 279 was an important molecular basis for the antigenic differences between nVarIBDV and vvIBDV. D279N substitution reduced the neutralizing ability of vvIBDV antiserum against nVarIBDV by affecting the binding ability of antibodies and antigens. Our results indicate that nVarIBDV has an infection transmission strategy that facilitates its survival by hiding viral pathogenicity and escaping antiserum neutralization, which not only has significant implications for the systemic cognition of viral genetic evolution and pathogenesis but also provides new ideas for the comprehensive prevention and control of IBDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.